First integrated system to demonstrate improved clinical outcomes in oncology using live patient tissue and the power of AI
Testing directly on viable human tissue, we also analyse data at the single cell level. In the landmark EXALT1 clinical study, our platform demonstrated for the first time that functional precision-oncology can improve patient outcome in a prospective interventional trial. Find out more on this page.
Interrogating activities directly in viable human tissue samples allows us to generate deep, clinically relevant insights into which molecules will deliver the most treatment benefit.
Exploring response at single cell resolution allows us to even distinguish on-target from off-target response in complex tissues
Powered by AI, for the benefit of the patient, we are pioneering new approaches in precision medicine, demonstrating for the first time that functional precision-oncology can improve patient outcome in a prospective interventional trial.
EXALT1: Clinical Trial
In the landmark study, it was demonstrated for the first time that our functional precision-oncology platform can improve patient outcome in a prospective interventional trial.
Pioneering work by our team has delivered a platform able to anticipate the effectiveness of cancer treatments in the clinic, using AI to analyse the activity of drugs in live patient samples, at single-cell resolution.
EXALT1 is the ﬁrst-ever prospective interventional study of its kind. Predictions made by the platform proposed which therapy would be most effective for late stage haematological cancer patients based on testing drug responses ex vivo in their own tissue samples.
Progression Free Survival
EXALT-1 demonstrated real-world patient selection capabilities by achieving a 55% response rate and statistically significant improvement in progression free survival over the prior line of therapy for patients that were treated following the platform’s recommendation.
In a post hoc analysis, patients receiving therapy recommended by the platform showed significantly improved outcomes compared to their prior treatments, whereas patients who received treatments other than the platform recommended therapy showed worse outcomes.
EXS21546 is our peripherally-restricted and selective antagonist of the Adenosine A2a Receptor. It is designed for anti-cancer immunotherapy, combatting adenosine related immunosuppressive effects, through T-cell activation.
To interrogate signaling and disease-relevant endpoints, prior to the Phase 1 clinical trial of EXS21546.
We analysed ex vivo activity in patient-derived whole blood samples and primary cancer cells from viable pancreas and lung tissue.
This study demonstrated potential for EXS21546 in cancer therapy, reducing tumour cell burden while inducing an expansion of the viable CD8+ T cell fraction.
EXS21546 is undergoing first-in-human studies (NCT04727138)